Merck (MRK) and a plaintiff suing the company over its human papillomavirus vaccine, Gardasil, have agreed to halt a trial after four weeks of proceedings, Reuters reported Tuesday, citing a company statement.
The plaintiff, Jennifer Robi, alleges that the vaccine caused her impaired mobility.
On Friday, the plaintiff's lawyers proposed discharging the jury and adjourning the case, and Merck agreed, provided that no financial or other consideration was exchanged, according to the news outlet.
Merck and Robi plan to reconvene with a new jury in a Los Angeles state court in September, the report added.
Merck did not immediately reply to MT Newswires' request for comment.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: 82.84, Change: -0.17, Percent Change: -0.20
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.